PET imaging study for rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy clinical trials.
This trial uses a special PET scan to see how an experimental drug, CIT-013, targets inflammation in the body. It's for people with rheumatoid arthritis to better understand how the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 85 years old
- You have been diagnosed with rheumatoid arthritis for at least 6 months
- You have active RA (with swollen and tender joints) and a disease activity score of 4.2 or higher
- If you are a man with a female partner who could get pregnant, you must use birth control and not donate sperm during the study and for 6 months after
- You are able to give written consent to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called CIT-013 for people with rheumatoid arthritis. It aims to see if CIT-013 can help reduce joint swelling and pain when added to your current treatment.
This study uses a special “light tracer” medicine with adalimumab to see where inflammation is in the gut (IBD) or joints (RA). If you have active disease, it may help doctors better target treatment by showing inflammation more clearly during scans.
This trial tests a new imaging scan (SPECT) that uses a special tracer (99mTc-TCR-FAPI) to see inflammation in the joints of people with rheumatoid arthritis. It aims to help doctors better understand and track disease activity.
This study tests whether a special scan can help doctors decide if you can safely reduce your rheumatoid arthritis medication. It may help you taper your treatment while keeping your disease under control.
This study tests a new imaging substance (called 99mTc-NTP 15-5) for people with hand arthritis (either rheumatoid arthritis or osteoarthritis). It aims to see if the substance can help doctors see joint inflammation and damage better, which could improve diagnosis and treatment.
This trial is testing a new imaging agent called RT01-89Zr to see if it can help detect solid tumors during PET/CT scans. It involves an injection of the agent followed by imaging, and may offer a more targeted way to visualize tumors.
Hear when a new RA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.